BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 10516085)

  • 1. Inhibition of cell-free human T-cell leukemia virus type 1 infection at a postbinding step by the synthetic peptide derived from an ectodomain of the gp21 transmembrane glycoprotein.
    Jinno A; Haraguchi Y; Shiraki H; Hoshino H
    J Virol; 1999 Nov; 73(11):9683-9. PubMed ID: 10516085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and mapping of functional domains on human T-cell lymphotropic virus type 1 envelope proteins by using synthetic peptides.
    Sagara Y; Inoue Y; Shiraki H; Jinno A; Hoshino H; Maeda Y
    J Virol; 1996 Mar; 70(3):1564-9. PubMed ID: 8627675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mapping of immunogenic regions of human T cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46.
    Palker TJ; Tanner ME; Scearce RM; Streilein RD; Clark ME; Haynes BF
    J Immunol; 1989 Feb; 142(3):971-8. PubMed ID: 2563272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence that the transmembrane domain proximal region of the human T-cell leukemia virus type 1 fusion glycoprotein gp21 has distinct roles in the prefusion and fusion-activated states.
    Wilson KA; Maerz AL; Poumbourios P
    J Biol Chem; 2001 Dec; 276(52):49466-75. PubMed ID: 11595747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. De novo design of peptide immunogens that mimic the coiled coil region of human T-cell leukemia virus type-1 glycoprotein 21 transmembrane subunit for induction of native protein reactive neutralizing antibodies.
    Sundaram R; Lynch MP; Rawale SV; Sun Y; Kazanji M; Kaumaya PT
    J Biol Chem; 2004 Jun; 279(23):24141-51. PubMed ID: 15060075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a novel neutralization epitope on envelope gp46 antigen of human T-cell-leukemia virus-type-II (HTLV-II).
    Tanaka Y; Tanaka R; Hoshino H
    Int J Cancer; 1994 Dec; 59(5):655-60. PubMed ID: 7525496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric synthetic peptides containing two immunodominant epitopes from the envelope gp46 and the transmembrane gp21 glycoproteins of HTLV-I virus.
    Hernández Marin M; Castellanos Pentón P; Márquez Bocalandro Y; Pozo Peña L; Díaz Navarro J; González López LJ
    Biochem Biophys Res Commun; 2001 Nov; 289(1):1-6. PubMed ID: 11708767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric synthetic peptides from the envelope (gp46) and the transmembrane (gp21) glycoproteins for the detection of antibodies to human T-cell leukemia virus type II.
    Hernández Marin M; Castellanos Pentón P; Márquez Bocalandro Y; Pozo Peña L; Díaz Navarro J; González López LJ
    Biochem Biophys Res Commun; 2001 Nov; 289(1):7-12. PubMed ID: 11708768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification, using synthetic peptides, of the minimum amino acid sequence from the retroviral transmembrane protein p15E required for inhibition of lymphoproliferation and its similarity to gp21 of human T-lymphotropic virus types I and II.
    Ruegg CL; Monell CR; Strand M
    J Virol; 1989 Aug; 63(8):3250-6. PubMed ID: 2746730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection of rabbits against HTLV-II infection with a synthetic peptide corresponding to HTLV-II neutralization region.
    Kariya N; Hayashi K; Hoshino H; Tanaka Y; Koirala TR; Ohara N; Miyamoto K; Akagi T
    Arch Virol; 1996; 141(3-4):471-80. PubMed ID: 8645089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of type-specific linear epitopes in the glycoproteins gp46 and gp21 of human T-cell leukemia viruses type I and type II using synthetic peptides.
    Horal P; Hall WW; Svennerholm B; Lycke J; Jeansson S; Rymo L; Kaplan MH; Vahlne A
    Proc Natl Acad Sci U S A; 1991 Jul; 88(13):5754-8. PubMed ID: 1712105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Host range of human T-cell leukemia virus type I analyzed by a cell fusion-dependent reporter gene activation assay.
    Okuma K; Nakamura M; Nakano S; Niho Y; Matsuura Y
    Virology; 1999 Feb; 254(2):235-44. PubMed ID: 9986790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trypsin-sensitive and -resistant components in human T-cell membranes required for syncytium formation by human T-cell lymphotropic virus type 1-bearing cells.
    Sagara Y; Ishida C; Inoue Y; Shiraki H; Maeda Y
    J Virol; 1997 Jan; 71(1):601-7. PubMed ID: 8985389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a neutralization epitope on the envelope gp46 antigen of human T cell leukemia virus type I and induction of neutralizing antibody by peptide immunization.
    Tanaka Y; Zeng L; Shiraki H; Shida H; Tozawa H
    J Immunol; 1991 Jul; 147(1):354-60. PubMed ID: 1711082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble recombinant HTLV-1 surface glycoprotein competitively inhibits syncytia formation and viral infection of cells.
    Jassal SR; Lairmore MD; Leigh-Brown AJ; Brighty DW
    Virus Res; 2001 Oct; 78(1-2):17-34. PubMed ID: 11520577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural and immunogenicity analysis of chimeric B-cell epitope constructs derived from the gp46 and gp21 subunits of the envelope glycoproteins of HTLV-1.
    Sundaram R; Beebe M; Kaumaya PT
    J Pept Res; 2004 Feb; 63(2):132-40. PubMed ID: 15009534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crystal structure of human T cell leukemia virus type 1 gp21 ectodomain crystallized as a maltose-binding protein chimera reveals structural evolution of retroviral transmembrane proteins.
    Kobe B; Center RJ; Kemp BE; Poumbourios P
    Proc Natl Acad Sci U S A; 1999 Apr; 96(8):4319-24. PubMed ID: 10200260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequence analysis of an immunogenic and neutralizing domain of the human T-cell lymphoma/leukemia virus type I gp46 surface membrane protein among various primate T-cell lymphoma/leukemia virus isolates including those from a patient with both HTLV-I-associated myelopathy and adult T-cell leukemia.
    Sherman MP; Dube S; Spicer TP; Kane TD; Love JL; Saksena NK; Iannone R; Gibbs CJ; Yanagihara R; Dube DK
    Cancer Res; 1993 Dec; 53(24):6067-73. PubMed ID: 8261424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of neutralizing antibodies against human T-cell leukemia virus type 1 using a cell-free infection system and polymerase chain reaction.
    Haraguchi Y; Yang DW; Handa A; Shimizu N; Tanaka Y; Hoshino H
    Int J Cancer; 1994 Nov; 59(3):416-21. PubMed ID: 7927951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of new epitopes recognized by human monoclonal antibodies with neutralizing and antibody-dependent cellular cytotoxicity activities specific for human T cell leukemia virus type 1.
    Kuroki M; Nakamura M; Itoyama Y; Tanaka Y; Shiraki H; Baba E; Esaki T; Tatsumoto T; Nagafuchi S; Nakano S
    J Immunol; 1992 Aug; 149(3):940-8. PubMed ID: 1378869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.